Povrchové markery leukemických kmenových buněk u chronické myeloidní leukémie

Leukemické kmenové buňky u CML

Abstract

The treatment with tyrosine kinase inhibitors has revolutionized management of CML, but only ~ 40 % of patients reach treatment-free remission. One of the underlying causes are persisting leukemic stem cells (LSCs) which are resistant to therapy and survive in quiescent form in the bone marrow niche. This LSC pool can serve as a source of CML reoccurrence and mutation acquisition, which can lead to treatment resistance and disease relapse. Thus, the ideal therapy goal is a complete disease eradication along with LSCs. However, specific therapeutic targets are lacking, and even monitoring of these rare cells is problematic. Therefore, there has been intense research on finding specific LSC markers which would allow distinction of LSCs from normal stem cells, description of LSC biology, and identification of potential therapeutic targets. This article reviews recent studies and clinical trials involved in the problematics of surface LSC markers in CML.